Strategic Partnerships Leverage Exai Bio’s AI-driven RNA liquid biopsy platform and established collaborations to pursue co-development or integrated diagnostics opportunities with oncology centers, CROs, and QLH platforms that focus on early cancer detection and treatment response monitoring.

Clinical Validation Target institutional buyers with Exai’s published data on early-stage cancer detection across multiple cancer types from large cohorts, emphasizing potential to shorten diagnostic pathways and improve accuracy in screening programs.

Executive Leadership Engage board-level and senior leadership connections, particularly with Dr. Hani Goodarzi's network and the new CEO and board member Karen Knudsen, to open strategic advisory and funding-influenced sales discussions and greater credibility with partners.

Market Differentiation Highlight the single blood test capable of multi-cancer early detection using RNA-based signals and AI, positioning against traditional biomarkers to appeal to payers, health systems, and employers seeking proactive cancer surveillance and cost savings.

Expansion Readiness Position Exai Bio for deployment in collaborative trials and real-world evidence studies with academic and industry partners (e.g., I-SPY 2, Quantum Leap Collaborative) to demonstrate treatment-response monitoring, increasing opportunities for adoption and scale.